查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095030

微創胸腔外科手術市場－2026-2032年全球市場預測

Minimally Invasive Thoracic Surgery Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，微創胸腔外科手術市場將成長至 51.8 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 29.5億美元
預計年份：2026年 31.9億美元
預測年份 2032 51.8億美元
複合年成長率 (%) 8.35%

微創胸腔外科手術（MITS）正在革新肺癌、縱膈疾病、胸膜疾病、食道疾病、氣胸和良性胸部病變的治療，它在減輕手術負擔的同時，仍能維持臨床療效。該領域涵蓋了電視輔助胸腔鏡手術（VATS）、機器人輔助胸腔鏡手術（RATS）、單孔入路、劍突下入路、導航輔助支氣管鏡切除術、先進的影像技術以及先進的能量治療和吻合器技術。同儕審查的證據支持這些技術的應用，這些證據表明，對於合適的患者，與傳統開胸手術相比，微創手術通常可以縮短住院時間、減輕手術全期疼痛、加快功能恢復、減少傷口相關併發症並改善術後肺功能。肺癌篩檢的增加、慢性呼吸系統疾病的沉重負擔、人口老化帶來的高手術風險，以及醫療系統為提高手術室效率和減少不必要的住院治療而面臨的壓力，都進一步推動了這一需求。隨著胸腔外科計畫的擴展，臨床卓越性越來越依賴多學科的病例選擇、外科培訓、標準化的手術全期期流程，以及在影像、麻醉、手術器械和數位化手術規劃方面的投入。

微創胸腔外科領域的變革性變化

微創胸腔外科領域正從專注於單一手術的創新轉向利用數位技術的整合式診療路徑。胸腔鏡輔助手術（VATS）仍是切除術、楔形切除術、胸腺切除術、胸膜切除術和切除術切除術等手術的成熟平台。同時，由於機器人輔助系統具有卓越的操控性、防手震功能、3D可視化和符合人體工學的優勢，其在複雜解剖操作、縫合和淋巴結評估等方面的臨床應用日益增多。一個重要的轉變是解剖性切除術（尤其是肺段切除術）的興起，旨在盡可能保留肺組織。越來越多的證據支持這一趨勢，相關指南也對部分早期非小細胞肺癌病例給予了更高的認可。這使得高解析度電腦斷層掃描（CT）、3D重建、肺段間平面辨識、螢光成像和精確的結節定位變得日益重要。另一項突破性轉變是診斷與治療的融合。先進的支氣管鏡檢查、錐狀射束CT、電磁感應或機器人導航以及影像引導定位正在幫助外科醫生處理篩檢中發現的較小、位置較深的肺結節。早期術後復健計畫也透過優先考慮減少止痛藥的使用、早期體能活動、最佳化胸腔引流和早期出院，正在改變臨床經濟狀況。同時，該專業也面臨許多挑戰，包括資金投入、先進平台取得途徑的差異、學習曲線的差異、保險報銷的複雜性以及系統認證的必要性。

人工智慧在微創胸腔外科手術的累積影響

人工智慧（AI）正對微創胸腔外科手術的整個流程產生累積影響，涵蓋篩檢和診斷、術前規劃、術中引導以及術後後續觀察等各個環節。在肺癌治療過程中，AI驅動的影像分析能夠輔助臨床醫生高效管理低劑量CT篩檢計畫產生的大量影像數據，包括結節檢測、體積追蹤、惡性腫瘤風險分層以及放射科工作流程優先排序。在術前規劃中，機器學習和電腦視覺技術可以支援3D重建、血管和支氣管定位、肺裂評估以及基於模擬的解剖切除演練。在手術過程中，AI在器械追蹤、手術階段識別、即時決策支援、自動記錄和品質評估等方面的重要性日益凸顯，但其在臨床應用中仍需經過嚴格的檢驗、互通性、網路安全以及人工監督。雖然人工智慧驅動的機器人和數位平台有潛力提高複雜微創胸腔外科手術的一致性，但短期內，能夠減少患者選擇、併發症預測、手術室排班和術後恢復管理等方面差異的決策支援工具可能更有價值。負責任地整合人工智慧需要透明的演算法、代表性的資料集、偏差監控、合規性以及臨床醫生培訓，從而使自動化能夠增強而非取代外科醫生的判斷。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

在亞太地區，由於多個國家肺癌發生率高、癌症篩檢力度加大、三級醫療機構的診療能力提升，以及已開發都市區機器人和胸腔鏡手術技術的快速普及，微創胸腔外科手術的需求日益成長。在中國、日本、韓國、印度、澳洲和東南亞國家，胸腔腫瘤的臨床診療流程正透過影像診斷、多學科腫瘤諮詢和培訓計畫得到加強，但都市區之間的醫療資源取得仍然存在差距。在北美，微創胸腔外科手術計畫已較為成熟，胸腔鏡輔助手術（VATS）和機器人手術得到廣泛應用，針對高危險群制定了完善的肺癌篩檢指南，並高度重視早期復健（ERAR）和以門診為中心的照護（如臨床適用）。在拉丁美洲，微創胸腔外科手術正在各大轉診醫院逐步推廣，其中巴西和墨西哥是重要的臨床中心。然而，設備成本、專科醫生數量和保險覆蓋範圍仍然影響著醫療服務的可及性。在歐洲，癌症患者受益於以指南為基礎的治療、較高的專科醫生培訓網路參與率以及健全的公共醫療體系，這些體系支持標準化的胸部腫瘤服務，儘管西歐、南歐、中歐和東歐的實施情況有所不同。在中東，對專科外科中心、腫瘤基礎設施和醫學教育的投資正在增加，尤其是在高所得醫療體系中。同時，在非洲，儘管區域中心在胸腔外科和癌症治療方面的能力有所提高，但它們仍然面臨著許多限制，例如診斷延遲、專科醫生短缺以及先進手術平台的獲取途徑有限。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體進行分析。

在東協，隨著新加坡、泰國、馬來西亞、越南、印尼和菲律賓等國不斷拓展胸腔腫瘤和先進外科醫療服務，微創胸腔外科的重要性日益凸顯。然而，各地區在醫院基礎設施、醫療專業人員培訓和保險覆蓋範圍方面存在差異。在海灣合作理事會（GCC）國家，透過投資建設先進的急診醫院、癌症中心、機器人手術計畫以及開展國際臨床合作，微創胸腔外科的普及速度正在加快，其重點在於減少海外就醫，並提升國內專科醫療水平。歐盟透過協調醫療設備法規、進行跨境臨床研究、癌症篩檢計畫和專業教育來支持微創胸腔外科的發展，但各國的報銷和採購機制仍存在差異。金磚國家面臨不同的機會和挑戰。中國和印度擁有龐大的患者群體和不斷擴大的手術能力，而巴西和南非則是該地區的核心轉診醫療機構。俄羅斯雖然在主要城市擁有先進的胸腔外科醫療能力，但面臨地理上的就醫障礙。七國集團（G7）擁有世界上一些最成熟的胸腔外科醫療體系，廣泛採用實證癌症治療方案、先進影像技術、機器人手術平台和臨床品質改進舉措。北約成員國與許多高所得的歐洲和北美醫療體系重疊，其軍事和民用醫療創新、創傷治療經驗、數位醫療基礎設施和先進的外科培訓能夠支持胸腔外科專科手術流程的標準化和穩定性。

對主要微創胸腔外科手術市場關鍵國家的深入分析。

美國擁有全球最先進的微創胸腔外科手術環境之一，這得益於肺癌篩檢指南、專業的癌症中心、機器人手術和胸腔鏡輔助手術（VATS）方面的專業技術，以及促進病患復健的方案。加拿大強調在其公共醫療體系內實現醫療服務的公平獲取，先進的胸腔外科手術主要集中在大型大學醫院和區域核心醫院。在墨西哥，微創胸腔外科手術能力正在公立和私立三級醫療機構中不斷擴展，尤其是在大都會圈，但不同地區和保險公司提供的服務存在差異。巴西是拉丁美洲胸腔外科手術的重要中心，擁有強大的學術實力，並在主要醫療中心不斷擴大VATS和機器人手術的應用，但資源分配仍然不平衡。在英國，微創技術被納入肺癌治療方案，適用於合適的患者，並利用國家癌症治療路徑、胸腔外科手術網路和多學科診療模式。德國擁有完善的醫院基礎設施和先進的外科培訓項目，內視鏡手術和機器人手術在大型醫療中心廣泛使用。法國將強大的公立醫院網路與以腫瘤治療為中心的護理協調相結合，為肺部和縱隔疾病的微創手術提供支持。俄羅斯已在主要大都市的醫療機構建立了先進的胸腔外科護理體系，但距離和區域基礎設施的限制影響了這些城市以外地區獲得醫療服務的機會。義大利和西班牙在胸腔外科領域擁有悠久的傳統，主要大學醫院和腫瘤醫院都已開展胸腔鏡輔助手術（VATS）和機器人手術計畫。在中國，微創胸腔外科手術正在迅速發展，這得益於大量的病例、國內臨床研究、機器人手術的日益普及以及對肺癌早期篩檢的日益重視。在印度，透過擴建三級醫療機構、私立專科醫療中心和外科培訓項目，微創胸腔外科手術正在取得進展，但成本問題和基礎設施不平衡仍然是主要的限制因素。日本在胸腔鏡手術、早期肺癌治療和技術驅動的精準手術方面擁有悠久的歷史和豐富的經驗。澳洲的醫療服務由專業的胸腔外科中心提供，這些中心擁有完善的、以指南為基礎的醫療保健體系和篩檢政策。韓國以其微創和機器人輔助胸腔外科手術技術的高普及率、強大的癌症治療基礎設施和先進的數位醫療能力而聞名。

為微創胸腔外科領域的領導者提供的實用建議

行業領導者應優先考慮循證應用而非技術主導的採購，將微創胸腔外科的投資與臨床適應症、手術量、外科醫生熟練程度以及可衡量的患者預後相匹配。醫院和外科網路應制定系統的培訓路徑，盡可能包括模擬、指導、雙主機或團隊學習，以及與胸腔鏡輔助手術 (VATS)、機器人輔助手術和高級支氣管鏡檢查相結合的工作流程的能力評估。決策者應規範早期復健方案、疼痛管理、胸管引流策略和出院標準，以減少胸腔外科計畫之間的差異。為支持精準手術，領導者應投資於整合影像、 3D規劃、結節定位、螢光引導以及連接放射科、呼吸系統醫療設備、麻醉科、病理科、腫瘤科和外科的互通性資料系統。人工智慧的應用應從檢驗的用例入手，例如支援影像診斷工作流程、風險分層、文件記錄和品質分析，並應同時建立關於偏見、隱私、網路安全和臨床課責的管治。採購團隊應評估整個流程的價值，包括儀器使用、維護、訓練、手術室使用時間、併發症減少以及臨床流程效率。最後，醫療系統應透過中心輻射轉診模式、遠距指導、區域培訓合作以及追蹤安全性、公平性和長期腫瘤治療結果的結局登記系統來擴大服務覆蓋範圍。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，基於檢驗的臨床、監管、流行病學和醫療保健系統資訊來源。此調查方法重點在於同行評審的外科文獻、臨床實踐指南、公共衛生出版物、癌症登記資訊、篩檢建議、醫療設備監管參考資料、醫院治療方案證據以及胸腔外科、腫瘤學、呼吸內科、放射學和麻醉學領域權威學會的共識聲明。證據的評估標準包括臨床相關性、時效性、可重複性和對各種手術的適用性，包括胸腔鏡輔助手術（VATS）、機器人輔助胸腔鏡手術、肺段切除術術、肺葉切除術、縱隔手術、胸膜手術以及肺結節從診斷到治療的整個流程。區域、群體和國家層面的見解來自公開的醫療保健基礎設施指標、癌症醫療保健政策、手術能力趨勢、技術採納徵兆以及與醫療服務可及性相關的證據，而未依賴市場規模、市場佔有率或預測假設。本分析避免了未經證實的論斷，並區分了成熟的臨床實踐和新興創新，尤其是在人工智慧驅動的診斷成像、機器人手術和數位化決策支援領域。研究結果以執行摘要的形式呈現，旨在為策略決策、技術評估、臨床專案開發和政策規劃提供支援。

結論

微創胸腔外科手術已成為現代胸腔外科的核心，其發展動力源自於對更安全手術、更快復健、更精準癌症治療和更有效率醫療服務的需求。該領域正透過結合胸腔鏡輔助手術（VATS）、機器人輔助手術、先進影像技術、肺保留切除術、促進復健的方案以及人工智慧輔助決策等手段不斷進步。雖然在擁有完善的專科培訓體系、多學科診療路徑、影像基礎設施和報銷制度的地區，微創胸腔外科手術的普及程度最高，但在技術和胸腔外科醫療專業知識匱乏的地區，仍然存在差距。未來的發展取決於平衡創新與實證醫學、提升醫療專業人員的能力、加強治療結果的評估，以及確保數位化工具和機器人平台能夠提供具有臨床永續的價值。投資於標準化治療路徑、檢驗的人工智慧應用、先進的視覺化技術和公平的醫療服務模式的醫療機構，將更有利於改善肺癌和其他胸部疾病的治療效果，同時支持外科醫療的永續轉型。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 微創胸腔外科手術市場：依手術類型分類

  • 肺切除術
    • 切除術
    • 節段性切除術
    • 楔形切除術
    • 全肺切除術
    • 肺減容手術
  • 食道手術
    • 切除術
    • 抗逆流手術
    • 肌切開術
  • 縱膈手術
    • 胸腺切除術
    • 縱膈腫瘤切除術
    • 淋巴結清除術
  • 胸膜手術
    • 胸膜固定術
    • 去皮
    • 切除術
    • 胸膜切片檢查
  • 交感神經系統手術

第8章 微創胸腔外科市場：依產品類型分類

  • 外科手術系統
    • 胸腔影像系統
    • 機器人手術平台
  • 手術器械
    • 內視鏡手用器械
    • 內視鏡吻合器
    • 能源設備
      • 電外科設備
      • 超音波設備
      • 先進的雙極裝置
    • 吸塵清潔裝置
  • 存取裝置
    • 套管針和港口
    • 穿刺針
    • 傷口保護
  • 封堵和止血產品
    • 縫線和夾子
    • 釘線加固
    • 密封劑和止血劑
  • 醫學影像與導航
    • 術中影像系統
    • 螢光成像系統
    • 導航地圖系統

第9章 微創胸腔外科市場：依適應症分類

  • 惡性胸腔疾病
    • 原發性肺癌
      • 早期非小細胞肺癌
      • 局部晚期非小細胞肺癌
    • 肺轉移性病變
    • 食道癌
    • 縱膈惡性腫瘤
  • 健康胸部疾病
    • 氣胸
    • 積膿
    • 良性食道疾病
      • 胃食道逆流症
      • 賁門失弛症
    • 縱膈囊腫和良性腫瘤
    • 多汗症
    • 良性肺結節

第10章 微創胸腔外科手術市場：依最終用戶分類

  • 醫院
    • 三級醫療機構
    • 當地醫院
    • 專業胸腔科中心
  • 門診手術中心
  • 專科診所
  • 學術研究機構

第11章 微創胸腔外科市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 微創胸腔外科市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 微創胸腔外科手術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardio Medical GmbH
  • CONMED Corporation
  • Cook Medical LLC
  • Dextera Surgical, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare, Inc.
  • Grena Ltd.
  • Intuitive Surgical, Inc.
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Koninklijke Philips NV
  • LivaNova plc
  • Medela Healthcare
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • Sklar Surgical Instruments
  • Smith & Nephew plc
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-3A2E844FEF43

The Minimally Invasive Thoracic Surgery Market is projected to grow by USD 5.18 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.95 billion
Estimated Year [2026] USD 3.19 billion
Forecast Year [2032] USD 5.18 billion
CAGR (%) 8.35%

Minimally invasive thoracic surgery (MITS) is reshaping the management of lung cancer, mediastinal disorders, pleural disease, esophageal conditions, pneumothorax, and benign thoracic pathology by reducing surgical trauma while preserving clinical effectiveness. The field spans video-assisted thoracoscopic surgery (VATS), robotic-assisted thoracic surgery (RATS), uniportal approaches, subxiphoid access, navigational bronchoscopy-assisted resection, enhanced imaging, and advanced energy and stapling technologies. Its adoption is supported by peer-reviewed evidence showing that minimally invasive approaches are commonly associated with shorter hospital stays, lower perioperative pain, faster functional recovery, fewer wound-related complications, and improved postoperative pulmonary preservation when compared with conventional open thoracotomy in appropriately selected patients. Demand is reinforced by rising lung cancer screening activity, a high burden of chronic respiratory disease, aging populations with higher surgical risk, and health-system pressure to improve operating room efficiency and reduce avoidable inpatient utilization. As thoracic programs expand, clinical excellence increasingly depends on multidisciplinary case selection, surgeon training, standardized perioperative pathways, and investment in imaging, anesthesia, instrumentation, and digital surgical planning.

Transformative Shifts in the Minimally Invasive Thoracic Surgery Landscape

The minimally invasive thoracic surgery landscape is moving from procedure-specific innovation toward integrated, digitally enabled care pathways. VATS remains a widely established platform for lobectomy, segmentectomy, wedge resection, thymectomy, pleural procedures, and sympathectomy, while robotic-assisted systems are gaining clinical relevance for complex dissections, suturing, and lymph node assessment due to enhanced dexterity, tremor filtration, three-dimensional visualization, and ergonomic advantages. A major shift is the rise of lung-sparing anatomical resections, particularly segmentectomy, supported by growing evidence and guideline recognition for selected early-stage non-small cell lung cancer cases. This has increased the importance of high-resolution computed tomography, three-dimensional reconstruction, intersegmental plane identification, fluorescence imaging, and precise nodule localization. Another transformative change is the convergence of diagnostics and therapy, with advanced bronchoscopy, cone-beam CT, electromagnetic or robotic navigation, and image-guided localization helping surgeons manage smaller and deeper pulmonary nodules detected through screening. Enhanced recovery after surgery protocols are also changing clinical economics by prioritizing opioid-sparing analgesia, early mobilization, chest-tube optimization, and faster discharge. At the same time, the specialty is addressing persistent barriers, including capital investment, unequal access to advanced platforms, learning-curve variability, reimbursement complexity, and the need for structured credentialing.

Cumulative Impact of Artificial Intelligence on Minimally Invasive Thoracic Surgery

Artificial intelligence is becoming a cumulative force across the minimally invasive thoracic surgery continuum, from screening and diagnosis to operative planning, intraoperative guidance, and postoperative surveillance. In lung cancer pathways, AI-enabled image analysis supports nodule detection, volumetric tracking, malignancy risk stratification, and workflow prioritization in radiology, helping clinicians manage growing imaging volumes created by low-dose CT screening programs. In surgical planning, machine learning and computer vision can assist with three-dimensional reconstruction, vascular and bronchial mapping, fissure assessment, and simulation-based rehearsal for anatomical resections. During procedures, AI is increasingly relevant for instrument tracking, surgical phase recognition, real-time decision support, automated documentation, and quality assessment, although clinical deployment requires rigorous validation, interoperability, cybersecurity, and human oversight. AI-enhanced robotics and digital platforms may improve consistency in complex minimally invasive thoracic procedures, but the strongest near-term value is likely to come from decision-support tools that reduce variability in patient selection, complication prediction, operating room scheduling, and recovery management. Responsible integration of AI requires transparent algorithms, representative datasets, bias monitoring, regulatory compliance, and clinician training so that automation strengthens, rather than replaces, surgical judgment.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

In Asia-Pacific, demand for minimally invasive thoracic surgery is supported by a high lung cancer burden in several countries, expanding cancer screening initiatives, growing tertiary hospital capacity, and rapid adoption of robotic and thoracoscopic techniques in advanced urban centers. China, Japan, South Korea, India, Australia, and Southeast Asian countries are strengthening thoracic oncology pathways through imaging access, multidisciplinary tumor boards, and training programs, though access remains uneven between metropolitan and rural settings. North America is characterized by mature minimally invasive thoracic surgery programs, broad use of VATS and robotic approaches, established lung cancer screening recommendations for high-risk populations, and strong emphasis on enhanced recovery and outpatient-oriented care where clinically appropriate. Latin America is seeing gradual expansion of minimally invasive thoracic procedures in major referral hospitals, with Brazil and Mexico acting as important clinical hubs; however, equipment affordability, specialist availability, and payer coverage continue to influence access. Europe benefits from guideline-driven cancer care, high participation in professional training networks, and strong public health systems that support standardized thoracic oncology services, although adoption patterns differ across Western, Southern, Central, and Eastern Europe. The Middle East is investing in specialized surgical centers, oncology infrastructure, and medical education, particularly in higher-income health systems, while Africa faces major constraints related to late diagnosis, limited specialist density, and restricted access to advanced operating platforms, even as regional centers develop capabilities in thoracic surgery and cancer care.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is becoming increasingly relevant for minimally invasive thoracic surgery as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines expand thoracic oncology and advanced surgical services, with regional variation driven by hospital infrastructure, workforce training, and insurance coverage. The GCC is accelerating adoption through investments in high-acuity hospitals, cancer centers, robotic surgery programs, and international clinical collaboration, with a focus on reducing outbound medical travel and improving domestic specialty care. The European Union supports minimally invasive thoracic surgery through harmonized medical device regulation, cross-border clinical research, cancer screening initiatives, and professional education, although reimbursement and procurement mechanisms remain country-specific. BRICS countries represent a diverse set of opportunities and constraints: China and India have large patient populations and expanding surgical capacity, Brazil and South Africa serve as regional referral anchors, and Russia maintains advanced thoracic capabilities in major cities while facing geographic access challenges. The G7 includes several of the world's most established thoracic surgery ecosystems, with strong adoption of evidence-based cancer pathways, advanced imaging, robotic platforms, and clinical quality improvement initiatives. NATO member countries overlap with many high-income European and North American systems where military and civilian medical innovation, trauma experience, digital health infrastructure, and advanced surgical training can support procedural standardization and resilience in specialized thoracic care.

Key Country Insights Across Major Minimally Invasive Thoracic Surgery Markets

The United States has one of the most developed minimally invasive thoracic surgery environments, supported by lung cancer screening guidance, specialized cancer centers, robotic and VATS expertise, and enhanced recovery protocols. Canada emphasizes equitable access within publicly funded healthcare systems, with advanced thoracic surgery concentrated in major academic and regional referral centers. Mexico is expanding minimally invasive thoracic capabilities in private and public tertiary hospitals, particularly in large urban areas, while access differs by geography and payer type. Brazil is Latin America's key thoracic surgery hub, with strong academic expertise and growing use of VATS and robotic approaches in major centers, although resource distribution remains uneven. The United Kingdom benefits from national cancer pathways, thoracic surgery networks, and multidisciplinary care, with minimally invasive approaches integrated into lung cancer treatment for suitable patients. Germany has extensive hospital infrastructure, advanced surgical training, and broad use of endoscopic and robotic techniques in high-volume centers. France combines strong public hospital networks with oncology-focused care coordination, supporting minimally invasive procedures for lung and mediastinal disease. Russia has advanced thoracic surgery capacity in leading metropolitan institutions, while distance and regional infrastructure affect access outside major cities. Italy and Spain maintain strong thoracic surgery traditions, with VATS and robotic programs present in major academic and cancer hospitals. China is rapidly scaling minimally invasive thoracic surgery, supported by large case volumes, domestic clinical research, expanding robotic adoption, and increasing focus on early lung cancer detection. India is advancing through tertiary hospitals, private specialty centers, and growing surgeon training, but affordability and uneven infrastructure remain key constraints. Japan has long-standing expertise in thoracoscopic surgery, early lung cancer management, and technology-enabled precision procedures. Australia operates through specialized thoracic units with strong guideline-based care and screening policy development. South Korea is recognized for high adoption of minimally invasive and robotic thoracic techniques, strong cancer care infrastructure, and advanced digital health capabilities.

Actionable Recommendations for Minimally Invasive Thoracic Surgery Leaders

Industry leaders should prioritize evidence-led adoption rather than technology-led purchasing by aligning minimally invasive thoracic surgery investments with clinical indications, procedural volume, surgeon proficiency, and measurable patient outcomes. Hospitals and surgical networks should build structured training pathways that include simulation, proctorship, dual-console or team-based learning where available, and competency assessment for VATS, robotic-assisted surgery, and advanced bronchoscopy-linked workflows. Decision-makers should standardize enhanced recovery protocols, pain management, chest drainage strategies, and discharge criteria to reduce variation across thoracic programs. To support precision surgery, leaders should invest in integrated imaging, three-dimensional planning, nodule localization, fluorescence guidance, and interoperable data systems that connect radiology, pulmonology, anesthesia, pathology, oncology, and surgery. AI adoption should begin with validated use cases such as imaging workflow support, risk stratification, documentation, and quality analytics, accompanied by governance for bias, privacy, cybersecurity, and clinical accountability. Procurement teams should evaluate total procedural value, including instrument utilization, maintenance, training, operating room time, complication reduction, and pathway efficiency. Finally, health systems should expand access through hub-and-spoke referral models, tele-mentoring, regional training collaboratives, and outcome registries that track safety, equity, and long-term oncologic performance.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified clinical, regulatory, epidemiological, and healthcare-system sources. The methodology emphasizes peer-reviewed surgical literature, clinical practice guidelines, public health publications, cancer registry information, screening recommendations, medical device regulatory references, hospital pathway evidence, and consensus statements from recognized thoracic surgery, oncology, pulmonology, radiology, and anesthesia communities. Evidence was assessed for clinical relevance, recency, reproducibility, and applicability across procedure types such as VATS, robotic-assisted thoracic surgery, segmentectomy, lobectomy, mediastinal surgery, pleural procedures, and diagnostic-to-therapeutic lung nodule workflows. Regional, group, and country insights were synthesized from publicly available healthcare infrastructure indicators, cancer care policies, surgical capacity patterns, technology adoption signals, and access-related evidence without using market sizing, market share, or forecasting assumptions. The analysis avoids unsupported claims and distinguishes established clinical practice from emerging innovation, particularly in AI-enabled imaging, robotic surgery, and digital decision support. Findings are presented as an executive synthesis to support strategic decision-making, technology assessment, clinical program development, and policy-aware planning.

Conclusion

Minimally invasive thoracic surgery has become a central component of modern thoracic care, driven by the need for safer procedures, faster recovery, precision cancer treatment, and efficient healthcare delivery. The field is advancing through the combined impact of VATS, robotic-assisted surgery, advanced imaging, lung-sparing resections, enhanced recovery protocols, and AI-supported decision-making. Adoption is strongest where specialist training, multidisciplinary pathways, imaging infrastructure, and reimbursement alignment are well established, while disparities persist across regions with limited access to technology and thoracic expertise. The next phase of progress will depend on balancing innovation with evidence, expanding workforce capability, strengthening outcome measurement, and ensuring that digital tools and robotic platforms deliver clinically meaningful value. Organizations that invest in standardized care pathways, validated AI applications, advanced visualization, and equitable access models will be best positioned to improve outcomes in lung cancer and other thoracic diseases while supporting sustainable surgical transformation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Minimally Invasive Thoracic Surgery Market, by Procedure Type

  • 7.1. Introduction
  • 7.2. Lung Resection
    • 7.2.1. Lobectomy
    • 7.2.2. Segmentectomy
    • 7.2.3. Wedge Resection
    • 7.2.4. Pneumonectomy
    • 7.2.5. Lung Volume Reduction Surgery
  • 7.3. Esophageal Procedures
    • 7.3.1. Esophagectomy
    • 7.3.2. Anti-Reflux Surgery
    • 7.3.3. Myotomy
  • 7.4. Mediastinal Procedures
    • 7.4.1. Thymectomy
    • 7.4.2. Mediastinal Tumor Resection
    • 7.4.3. Lymph Node Dissection
  • 7.5. Pleural Procedures
    • 7.5.1. Pleurodesis
    • 7.5.2. Decortication
    • 7.5.3. Bullectomy
    • 7.5.4. Pleural Biopsy
  • 7.6. Sympathetic Procedures

8. Minimally Invasive Thoracic Surgery Market, by Product Type

  • 8.1. Introduction
  • 8.2. Surgical Systems
    • 8.2.1. Thoracoscopic Video Systems
    • 8.2.2. Robotic Surgical Platforms
  • 8.3. Surgical Instruments
    • 8.3.1. Endoscopic Hand Instruments
    • 8.3.2. Endoscopic Stapling Devices
    • 8.3.3. Energy Devices
      • 8.3.3.1. Electrosurgical Devices
      • 8.3.3.2. Ultrasonic Devices
      • 8.3.3.3. Advanced Bipolar Devices
    • 8.3.4. Suction-Irrigation Devices
  • 8.4. Access Devices
    • 8.4.1. Trocars & Ports
    • 8.4.2. Access Needles
    • 8.4.3. Wound Protectors
  • 8.5. Closure & Hemostasis Products
    • 8.5.1. Sutures & Clips
    • 8.5.2. Staple Line Reinforcement Materials
    • 8.5.3. Sealants & Hemostatic Agents
  • 8.6. Imaging & Navigation
    • 8.6.1. Intraoperative Imaging Systems
    • 8.6.2. Fluorescence Imaging Systems
    • 8.6.3. Navigation & Mapping Systems

9. Minimally Invasive Thoracic Surgery Market, by Indication

  • 9.1. Introduction
  • 9.2. Malignant Thoracic Diseases
    • 9.2.1. Primary Lung Cancer
      • 9.2.1.1. Early-Stage Non-Small Cell Lung Cancer
      • 9.2.1.2. Locally Advanced Non-Small Cell Lung Cancer
    • 9.2.2. Metastatic Lung Lesions
    • 9.2.3. Esophageal Cancer
    • 9.2.4. Mediastinal Malignancies
  • 9.3. Benign Thoracic Diseases
    • 9.3.1. Pneumothorax
    • 9.3.2. Empyema
    • 9.3.3. Benign Esophageal Disorders
      • 9.3.3.1. Gastroesophageal Reflux Disease
      • 9.3.3.2. Achalasia
    • 9.3.4. Mediastinal Cysts And Benign Tumors
    • 9.3.5. Hyperhidrosis
    • 9.3.6. Benign Pulmonary Nodules

10. Minimally Invasive Thoracic Surgery Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
    • 10.2.1. Tertiary Care Hospitals
    • 10.2.2. Community Hospitals
    • 10.2.3. Specialty Thoracic Centers
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Specialty Clinics
  • 10.5. Academic And Research Institutes

11. Minimally Invasive Thoracic Surgery Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Minimally Invasive Thoracic Surgery Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Minimally Invasive Thoracic Surgery Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. B. Braun Melsungen AG
  • 15.2. Becton, Dickinson and Company
  • 15.3. Boston Scientific Corporation
  • 15.4. Cardio Medical GmbH
  • 15.5. CONMED Corporation
  • 15.6. Cook Medical LLC
  • 15.7. Dextera Surgical, Inc.
  • 15.8. Fujifilm Holdings Corporation
  • 15.9. GE HealthCare, Inc.
  • 15.10. Grena Ltd.
  • 15.11. Intuitive Surgical, Inc.
  • 15.12. Johnson & Johnson
  • 15.13. KARL STORZ SE & Co. KG
  • 15.14. Koninklijke Philips N.V.
  • 15.15. LivaNova plc
  • 15.16. Medela Healthcare
  • 15.17. Medtronic plc
  • 15.18. Merit Medical Systems, Inc.
  • 15.19. Olympus Corporation
  • 15.20. Sklar Surgical Instruments
  • 15.21. Smith & Nephew plc
  • 15.22. Stryker Corporation
  • 15.23. Teleflex Incorporated
  • 15.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LUNG RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LUNG RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LOBECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LOBECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LOBECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEGMENTECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEGMENTECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEGMENTECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WEDGE RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WEDGE RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WEDGE RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG VOLUME REDUCTION SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LUNG VOLUME REDUCTION SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG VOLUME REDUCTION SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ESOPHAGEAL PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ESOPHAGEAL PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ESOPHAGEAL PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ESOPHAGECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ESOPHAGECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ESOPHAGECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-REFLUX SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-REFLUX SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-REFLUX SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MYOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MYOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MYOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MEDIASTINAL PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDIASTINAL PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEDIASTINAL PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYMECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THYMECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYMECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MEDIASTINAL TUMOR RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDIASTINAL TUMOR RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MEDIASTINAL TUMOR RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LYMPH NODE DISSECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLEURAL PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLEURAL PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLEURAL PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLEURODESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLEURODESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLEURODESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DECORTICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DECORTICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DECORTICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BULLECTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BULLECTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BULLECTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLEURAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLEURAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLEURAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYMPATHETIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYMPATHETIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYMPATHETIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SURGICAL SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SURGICAL SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURGICAL SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THORACOSCOPIC VIDEO SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THORACOSCOPIC VIDEO SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THORACOSCOPIC VIDEO SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ROBOTIC SURGICAL PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ROBOTIC SURGICAL PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ROBOTIC SURGICAL PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SURGICAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOSCOPIC HAND INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOSCOPIC HAND INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOSCOPIC HAND INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOSCOPIC STAPLING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOSCOPIC STAPLING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOSCOPIC STAPLING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENERGY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENERGY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENERGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ELECTROSURGICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ELECTROSURGICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ELECTROSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ULTRASONIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ULTRASONIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ULTRASONIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADVANCED BIPOLAR DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADVANCED BIPOLAR DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ADVANCED BIPOLAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SUCTION-IRRIGATION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SUCTION-IRRIGATION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SUCTION-IRRIGATION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACCESS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACCESS DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ACCESS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TROCARS & PORTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TROCARS & PORTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TROCARS & PORTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACCESS NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACCESS NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACCESS NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL WOUND PROTECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL WOUND PROTECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL WOUND PROTECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CLOSURE & HEMOSTASIS PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CLOSURE & HEMOSTASIS PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CLOSURE & HEMOSTASIS PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SUTURES & CLIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SUTURES & CLIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SUTURES & CLIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL STAPLE LINE REINFORCEMENT MATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL STAPLE LINE REINFORCEMENT MATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL STAPLE LINE REINFORCEMENT MATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEALANTS & HEMOSTATIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SEALANTS & HEMOSTATIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEALANTS & HEMOSTATIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMAGING & NAVIGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMAGING & NAVIGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMAGING & NAVIGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRAOPERATIVE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INTRAOPERATIVE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRAOPERATIVE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NAVIGATION & MAPPING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NAVIGATION & MAPPING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NAVIGATION & MAPPING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALIGNANT THORACIC DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MALIGNANT THORACIC DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALIGNANT THORACIC DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PRIMARY LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRIMARY LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PRIMARY LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EARLY-STAGE NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EARLY-STAGE NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EARLY-STAGE NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL METASTATIC LUNG LESIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL METASTATIC LUNG LESIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL METASTATIC LUNG LESIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MEDIASTINAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MEDIASTINAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MEDIASTINAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BENIGN THORACIC DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BENIGN THORACIC DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BENIGN THORACIC DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMOTHORAX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMOTHORAX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMOTHORAX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL EMPYEMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL EMPYEMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL EMPYEMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BENIGN ESOPHAGEAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BENIGN ESOPHAGEAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BENIGN ESOPHAGEAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACHALASIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ACHALASIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACHALASIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL MEDIASTINAL CYSTS AND BENIGN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL MEDIASTINAL CYSTS AND BENIGN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MEDIASTINAL CYSTS AND BENIGN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HYPERHIDROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HYPERHIDROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HYPERHIDROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BENIGN PULMONARY NODULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BENIGN PULMONARY NODULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BENIGN PULMONARY NODULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL SPECIALTY THORACIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SPECIALTY THORACIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL SPECIALTY THORACIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 290. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 292. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 309. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 310. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 311. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 312. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 314. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 315. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE